跳到正文
原文
BioPharma Dive· Gwendolyn Wu·· 4 天前AI 评分37

Sofinnova Partners 设立€7.25亿 crossover II 基金,支持临近商业化的生物医药及器械企业

One of Europe’s leading VCs banks a €725M ‘crossover’ fund

AI 导读

Sofinnova Partners 宣布募集7.25亿欧元(约合8.15亿美元)设立其迄今规模最大的 crossover 基金——Sofinnova Crossover II,计划投资于约15家临近商业化的生物制药和医疗器械公司,多数位于欧洲,同时保留对美国及其他地区初创企业的投资窗口。

正文

An article from site logo

Dive Brief // Emerging biotech

Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

Published Nov. 16, 2026

Gwendolyn Wu's headshot

A group of investors at Sofinnova Partners.

Sofinnova Partners announced Nov. 16, 2026 that it brought in 725 million euros for a fund that will support biotechs and medical device companies nearing commercialization. Permission granted by Sofinnova Partners

Dive Brief:

  • Sofinnova Partners, one of Europe’s premier life sciences investors, announced Monday it raised 725 million euros, or $815 million, for a second fund dedicated to companies that are close to commercializing their own products.
  • With the new “Sofinnova Crossover II,” the firm plans to invest in about 15 drugmakers and medical device developers, similar to what it did with an earlier fund in 2021. Most of those companies will likely be based in Europe, though Sofinnova will still look at startups from the U.S. and other countries, partner Kinam Hong told BioPharma Dive.
  • Biotech venture firms have raised more than $13 billion in fresh funding in 2026, according to an October report from investment firm William Blair. Crossover financings — the private fundings that often precede an initial public offering — “reaccelerated as the public market window reopened,” William Blair analysts wrote.

Dive Insight:

Sofinnova is debuting its new fund while biotechnology-focused venture capital firms continue to lean heavily into startups with drugs already in clinical testing. According to BioPharma Dive data tracking 26 of the sector’s most active investors, more than 70 private rounds this year have gone toward biotechs with prospects in Phase 1 trials or later.

The firm also aims to fix what Hong describes as a mislabeled perception that European drugmakers are “discount” companies. Hong helped lead Sofinnova’s initial investment in AbiVax, a publicly traded immune drugmaker now worth around $7 billion. He was also a believer in Verona Pharma, which brought a lung medication to market before it was acquired by Merck & Co. The new fund could support other maturing companies.  

“Europe doesn't have an innovation problem, what it has is a scale-up financing problem,” Hong said.

The latest crossover fund, which is Sofinnova’s largest yet, has already been put to work, infusing companies such as CellCentric and Hemab Therapeutics with cash to carry out clinical trials.

Sofinnova still supports early-stage biotechs, posting investments this year in startups such as Alethio Therapeutics, Bionyra and T-Therapeutics. Last year, it raised 650 million euros, or $750 million, to support young therapeutics and medtech makers.

“The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets,” said Antoine Papiernik, Sofinnova’s chairman and managing partner, in a statement.

Sofinnova has about 4 billion euros in assets under management.

来源:BioPharma Dive · biopharmadive.com